India Biosimilars Market to Gather Momentum in Coming Years, States Netscribes in Its Topical Report Available at MarketPublishers.com

17 Aug 2017 • by Natalie Aster

LONDON – Rising incidence of diseases like CHD and CVD, diabetes and cancer in India has resulted in the increasing demand for biosimilars and, thus, in the uptake of the country’s market for biosimilars.

Biosimilars are usually marketed at prices that are 25%-40% below the prices of original branded products, this has been the primary appeal to customers. Furthermore, elevating number of tertiary care centers spurs the adoption and usage of biosimilars in the country.

Escalating drug costs, patent expiries of biotechnology drugs and limited healthcare budgets globally have created lucrative opportunities for biosimilar manufacturers. Today, there aren’t too many participants in the market, it is dominated by a small number of companies leaving a room for new entrants.

However, high operating costs, required capital investment, strict regulatory norms and lack of widespread awareness about biosimilar products act as a drawback for the Indian biosimilars industry.

Despite the existing challenges, the Indian biosimilars market is set to gather momentum in the coming years with launches of new biosimilar products for chronic diseases treatment and with entering of new market players.

Netscribes’ topical research report, “Biosimilars Market in India 2017”, presents profound, unbiased insights into the current landscape of the Indian market for biosimilars, touches upon the historical development patterns of this country’s market, traces light on the market dynamics and examines the main factors and forces shaping the market. Besides, this publication points out the emerging growth opportunities and challenges, covers regulatory framework, presents a detailed analysis of the market structure and segmentation, and also delves into the competitive landscape. It contains comprehensive profiles of the top companies active in the domestic biosimilars market, reviews the recent industry developments and gives future projections for the Indian biosimilars market development up to 2020.

For other research reports worked out by this company follow to Netscribes page at MarketPublishers.com.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com